对非小细胞肺癌的生物学见解
Rafael Rosell1,2, Anisha Jain3, Jordi Codony-Servat4
1Germans Trias i Pujol Research Institute, Badalona 08028, Spain.
Cancer biology & medicine
|June 29, 2023
概括
非小细胞肺癌 (NSCLC) 细胞利用囊/谷氨酸抗载体 (xCT) 来控制氧化应激. 抑制xCT或向KRAS可以诱导细胞死亡途径,如铁和热,影响免疫治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 非小细胞肺癌 (NSCLC) 依赖细胞内囊来抵抗氧化应激,通常通过囊/谷氨酸抗载体 (xCT) 和SLC7A11载体.
- NRF2-KEAP1通路调节氧化应激,KEAP1/NRF2和p53中的突变激活NSCLC中的SLC7A11.
- 被破坏的囊摄取可以导致铁亡,一种由铁依赖性脂质过氧化驱动的细胞死亡形式.
研究的目的:
- 探索囊代谢和相关细胞死亡途径在NSCLC中的作用.
- 研究向囊摄取和特定的瘤驱动因素对瘤细胞死亡和免疫逃避的影响.
- 讨论KRAS G12C抑制剂和抵抗机制的进展.
主要方法:
- 分析系统xc- (xCT) 和SLC7A11在NSCLC氧化应激中的作用.
- 通过药理上抑制xCT或GPX4.4来研究ferroptosis诱导.
- 检查EGFR,ALK或KRAS驱动的NSCLC中通过向疗法诱导热的情况.
- 复习转硫途径在囊可用性和免疫功能中的作用.
- 讨论KRAS G12C抑制剂和抵抗机制.
主要成果:
- 抑制xCT或GPX4会诱导NSCLC细胞中的铁亡.
- 针对特定NSCLC亚型的向疗法激活了亡和亡.
- 囊的吸收受损和转硫路径的改变可能会损害CD8+T细胞的功能,可能会阻碍免疫治疗.
- 克拉斯G12C抑制剂代表了一项治疗突破,目前正在进行对耐药性的研究.
结论:
- 向囊代谢和诱导铁或热是NSCLC治疗的有希望的策略.
- 了解囊代谢,细胞死亡和免疫微环境之间的相互作用对于优化免疫治疗至关重要.
- 克拉斯G12C抑制剂为NSCLC患者提供了新的希望,需要继续研究克服耐药性.
关键词:
KRAS G12C等位基特异性抑制剂溶性载体家族7的成员11 (SLC7A11)铁性化 (ferroptosis) 是一种非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.核因子红色素2相关因子2 (NRF2)热致灭 (pyroptosis) 是一种致的过程.更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.0K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K